{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"62.91","upperLimit":"88.80","value":"77.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"}],"units":"Participants"}],"description":"CR=all of the following improvements: (1) bone marrow: ≤5% myeloblasts (including monocytic blast equivalent) and no lymphoblasts, with normal maturation of all cell lines, and return to age-adjusted normal cellularity; (2) osteomyelofibrosis absent/equal to \"mild reticulin fibrosis\"; (3) WBC ≤10 x 10\\^9 cells/L; Hgb ≥11 g/dL; platelets ≥100 x 10\\^9/L, ≤450 x 10\\^9/L; neutrophils ≥1.0 x 10\\^9/L; blasts=0%; neutrophil precursors reduced to ≤2%; monocytes ≤1 x 10\\^9/L; eosinophils ≤0.5 x 10\\^9/L; (4) extramedullary disease: complete resolution of extramedullary disease present pre-therapy, including palpable hepatosplenomegaly. Persistent low-level dysplasia was permitted. PR=all of the following improvements: (1) reduction of bone marrow blasts/blast equivalents by 50%, but remaining \\>5% of cellularity (except in cases with ≤5% bone marrow blasts at baseline); (2) normalization of peripheral blood indices per CR Criterion 3; (3) extra medullary disease response of CMR/CR or PMR/PR.","dispersionType":"95% Confidence Interval","groups":[{"description":"Pemigatinib 13.5 milligrams (mg) was self-administered once daily (QD) as oral tablets on an intermittent dosing (ID) schedule or continuous dosing (CD) schedule. Participants started pemigatinib 13.5 mg on the ID schedule (i.e., 2 weeks on/1 week off) as per the initial Protocol and on the CD schedule in 21-day cycles following a Protocol amendment.","id":"OG000","title":"Pemigatinib 13.5 mg"}],"paramType":"NUMBER","populationDescription":"Full Efficacy-Evaluable Population. Confidence intervals were calculated based on the exact method for binomial distribution. CMR=complete metabolic response; PMR=partial metabolic response. Response criteria by investigator assessment were the same for chronic phase (CP) and blast phase (BP).","reportingStatus":"POSTED","timeFrame":"up to 2513 days (120 21-day treatment cycles)","title":"Percentage of Participants Who Achieved a Best Overall Response of Complete Response (CR) or Partial Response (PR) as Determined by Investigator Assessment According to the Response Criteria for Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement","type":"SECONDARY","unitOfMeasure":"percentage of participants"}